Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases
- 1 January 2019
- book chapter
- Published by Elsevier
- Vol. 245, 119-144
Abstract
No abstract availableKeywords
This publication has 150 references indexed in Scilit:
- Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse modelsActa Neuropathologica, 2013
- Human iPSC-Derived Oligodendrocyte Progenitor Cells Can Myelinate and Rescue a Mouse Model of Congenital HypomyelinationCell Stem Cell, 2013
- Oligodendroglia metabolically support axons and contribute to neurodegenerationNature, 2012
- Phosphorylated olig1 localizes to the cytosol of oligodendrocytes and promotes membrane expansion and maturationGlia, 2012
- Glycolytic oligodendrocytes maintain myelin and long-term axonal integrityNature, 2012
- Metabolomics implicates altered sphingolipids in chronic pain of neuropathic originNature Chemical Biology, 2012
- Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiationGlia, 2011
- Multiple sclerosisThe Lancet, 2008
- Decreased spinal cord opioid receptor mRNA expression and antinociception in a Theiler's murine encephalomyelitis virus model of multiple sclerosisBrain Research, 2008
- Inactivation of N-Acyl Phosphatidylethanolamine Phospholipase D Reveals Multiple Mechanisms for the Biosynthesis of EndocannabinoidsBiochemistry, 2006